Aastrom Biosciences News

NCR Corp : RBC Capital Mkts initiated coverage of this company with a rating of Outperform and a price target of $28. Heidrick & Struggles : Avondale initiated coverage of this company with a rating of Mkt Perform and a price target of $17. kforce.com : Avondale initiated coverage of this company with a rating of Mkt Perform and a price target of ... (more)

Student Transportation : Stifel Nicolaus initiated coverage of this company with a rating of Buy and a price target of $7.3. Berry Petroleum : Barrington Research initiated coverage of this company with a rating of Outperform and a price target of $50. Forum Energy Tech.

The firm set a "buy" rating on the stock. A number of other firms have also recently commented on ASTM.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia ANN ARBOR, Mich., May 17, 2012 -- Aastrom Biosciences, Inc.

A number of other analysts have also recently weighed in on ASTM. Analysts at Oppenheimer reiterated a "market perform" rating on shares of Aastrom Biosciences in a research note to investors on Friday.

's stock had its "market perform" rating reiterated by equities research analysts at Oppenheimer in a research note issued to investors on Friday.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia ANN ARBOR, Mich., May 9, 2012 -- Aastrom Biosciences, Inc.

ANN ARBOR, Mich., May 7, 2012 -- Aastrom Biosciences, Inc. , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following webcast:

In part I of this series, Neostem and Aastrom stood out in a field of 6 stem cell biotechs with their advancing trials, recent financing, manufacturing capabilities and/or current revenue generation .